A 2006 paper in the journal Regulatory Toxicology and Pharmacology, with the asbestos industry’s go-to scientist David Bernstein as the lead author, concluded: “The value of the present and other similar studies is that they show that low exposures to pure chrysotile do not present a detectable risk to health. Since total dose over time decides the likelihood of disease occurrence and progression, they also suggest that the risk of an adverse outcome may be low if even any high exposures experienced were of short duration.” This paper was reproduced on the website of the Chrysotile Institute – which, in its previous guise as the Asbestos Institute, co-financed the work.

DM Bernstein and JA Hoskins. The health effects of chrysotile: Current perspective based upon recent data, Regulatory Toxicology and Pharmacology, volume 45, issue 3, pages 252–264, August 2006.